Thrivent Financial for Lutherans Acquires New Position in TransMedics Group, Inc. (NASDAQ:TMDX)

Thrivent Financial for Lutherans bought a new position in TransMedics Group, Inc. (NASDAQ:TMDX) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 26,196 shares of the company’s stock, valued at approximately $4,113,000. Thrivent Financial for Lutherans owned approximately 0.08% of TransMedics Group as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. State Board of Administration of Florida Retirement System boosted its holdings in shares of TransMedics Group by 8.6% in the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock worth $745,000 after acquiring an additional 780 shares during the period. Vanguard Group Inc. grew its holdings in TransMedics Group by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 1,889,094 shares of the company’s stock valued at $139,680,000 after buying an additional 23,979 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in shares of TransMedics Group by 8.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 297,324 shares of the company’s stock worth $21,985,000 after buying an additional 22,223 shares in the last quarter. Public Employees Retirement System of Ohio bought a new position in shares of TransMedics Group in the first quarter valued at approximately $1,588,000. Finally, Comerica Bank grew its stake in TransMedics Group by 1,072.5% during the first quarter. Comerica Bank now owns 14,422 shares of the company’s stock valued at $1,066,000 after acquiring an additional 13,192 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Performance

NASDAQ TMDX opened at $76.04 on Monday. The company has a 50-day simple moving average of $119.18 and a two-hundred day simple moving average of $137.77. TransMedics Group, Inc. has a 12-month low of $67.77 and a 12-month high of $177.37. The firm has a market cap of $2.55 billion, a price-to-earnings ratio of 80.89 and a beta of 2.08. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group (NASDAQ:TMDX) last released its earnings results on Monday, October 28th. The company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The company had revenue of $108.76 million during the quarter, compared to the consensus estimate of $115.00 million. During the same period last year, the firm posted ($0.12) EPS. The company’s revenue was up 63.7% on a year-over-year basis. On average, equities analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Transactions at TransMedics Group

In other news, insider Nicholas Corcoran sold 10,000 shares of the stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $176.02, for a total transaction of $1,760,200.00. Following the completion of the sale, the insider now directly owns 21,105 shares in the company, valued at approximately $3,714,902.10. This represents a 32.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward M. Basile sold 6,750 shares of the business’s stock in a transaction dated Tuesday, November 5th. The shares were sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,958 shares of company stock worth $5,230,528. Insiders own 7.00% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMDX. TD Cowen decreased their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Robert W. Baird decreased their price objective on shares of TransMedics Group from $200.00 to $150.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 29th. JPMorgan Chase & Co. dropped their target price on shares of TransMedics Group from $173.00 to $116.00 and set an “overweight” rating for the company in a research report on Tuesday, October 29th. Canaccord Genuity Group decreased their price target on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Finally, Needham & Company LLC reaffirmed a “hold” rating and set a $109.00 price objective on shares of TransMedics Group in a report on Friday. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.80.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.